Organon acquires biosimilar to Acterma
Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.
“Biosimilars continue to be a key growth driver for Organon, and this acquisition complements our existing business, enabling us to expand our immunology portfolio,” said Kevin Ali, Organon’s CEO. “We believe that by leveraging our commercial expertise and market access capabilities, there is considerable growth potential for this product.”
[Read more: AAM report: Generics, biosimilars generate $445B in savings]
Under the terms of the agreement, Organon has acquired the regulatory and commercial rights to Tofidence in the United States, available in three vial sizes, 80 mg/4 ml, 200 mg/10 ml and 400 mg/20 ml, for further dilution prior to intravenous infusion. Bio-Thera Solutions, the product developer, will maintain manufacturing rights for Tofidence for the U.S. market.
The agreement includes an upfront payment to Biogen, with Organon assuming the obligation to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments owed by Biogen to Bio-Thera Solutions.
[Read more: AAM: IRA hampers generic, biosimilar drug competition]